Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)

Methods and analysis In this placebo-controlled, double-blind, phase III trial, patients are being randomised in a 1:1:1 ratio to receive 9 mg or 18 mg of BI 1015550 or placebo two times per day over at least 52 weeks, stratified by use of background antifibrotics (nintedanib/pirfenidone vs neither)...

Full description

Bibliographic Details
Main Authors: Toby M Maher, Michael Kreuter, Vincent Cottin, Susanne Stowasser, Marlies S Wijsenbeek, Yi Liu, Fernando J Martinez, Luca Richeldi, Arata Azuma, Justin M Oldham, Claudia Valenzuela, Maud Gordat, Donald F Zoz
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:BMJ Open Respiratory Research
Online Access:https://bmjopenrespres.bmj.com/content/10/1/e001563.full

Internet

https://bmjopenrespres.bmj.com/content/10/1/e001563.full

Similar Items